HIV infection leads to selective depletion of CD4+ T cells and an increase in CD8+ T cells resulting in an inverted CD4:CD8 ratio which often persists despite antiretroviral therapy (ART). A low CD4:CD8 ratio is associated with AIDS and non-AIDS related morbidities. A positive association between CD4:CD8 ratio normalization and initiation of raltegravir containing regimens has been observed. We hypothesize that Integrase Strand Transfer Inhibitor (INSTI)-containing regimens are associated with shorter time to CD4:CD8 normalization relative to other ART regimens among treatment naïve patients.
Retrospective analysis of the Canadian Observational Cohort (CANOC), a collaboration of HIV-infected individuals initiating combination ART between 2000 and 2014. Participants starting on 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)/1 INSTI or a non-INSTI regimen on or after January 1, 2011 with a pre-treatment CD4:CD8 ratio <1.2 and ≥2 follow-up ratios within 6 months of treatment initiation were included. Kaplan Meier estimates were used to describe time to CD4:CD8 ratio normalization (CD4:CD8 ratio ≥1.2 on 2 consecutive measures ≥ 30 days apart). Multivariable proportional hazards models were used to estimate the association between ART class and time to CD4:CD8 normalization.
781 participants were included and followed for a median [IQR] 1.9 [1.0, 2.7] years. Median [IQR] age was 38 [31, 47] and 699 (90%) were men. 235 participants starting on INSTI-containing regimens were more likely to have a higher median [IQR] pre-treatment CD4 count (370 [225, 480] vs. 330 [210, 440], p=0.04) compared to those starting non-INSTI regimens. 35 (15%) participants on INSTI-containing regimens normalized their CD4:CD8 ratio with a 0.21 (95%CI 0.13, 0.28) probability of achieving normalization within 2 years. 63 (12%) of those on non-INSTI regimens normalized with a 0.11 (95%CI 0.08, 0.14) probability of achieving so within 2 years (p<0.01). After adjusting for pre-treatment CD4, viral load, risk factor, hepatitis B and C, those starting INSTI-containing regimens compared to other ART were more likely to achieve normalization (HR=1.75, 95%CI 1.10, 2.77).
Our results provide further evidence that initiation of INSTI-containing regimens results in a higher rate of normalization of the CD4:CD8 ratio in ART naïve subjects. Whether this is associated with lower rates of comorbidity or improved survival requires further study.